Takeda Pharmaceutical (TAK) Debt to Equity (2018 - 2025)
Takeda Pharmaceutical (TAK) has 8 years of Debt to Equity data on record, last reported at $0.16 in Q1 2025.
- For Q1 2025, Debt to Equity rose 9.31% year-over-year to $0.16; the TTM value through Mar 2025 reached $0.16, up 9.31%, while the annual FY2025 figure was $0.16, 9.31% up from the prior year.
- Debt to Equity reached $0.16 in Q1 2025 per TAK's latest filing, up from $0.15 in the prior quarter.
- Across five years, Debt to Equity topped out at $0.76 in Q1 2022 and bottomed at $0.14 in Q1 2023.
- Average Debt to Equity over 5 years is $0.27, with a median of $0.15 recorded in 2021.
- Peak YoY movement for Debt to Equity: surged 416.03% in 2022, then tumbled 81.98% in 2023.
- A 5-year view of Debt to Equity shows it stood at $0.15 in 2021, then soared by 416.03% to $0.76 in 2022, then crashed by 81.98% to $0.14 in 2023, then grew by 5.49% to $0.15 in 2024, then grew by 9.31% to $0.16 in 2025.
- Per Business Quant database, its latest 3 readings for Debt to Equity were $0.16 in Q1 2025, $0.15 in Q1 2024, and $0.14 in Q1 2023.